IN2012DN00592A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00592A
IN2012DN00592A IN592DEN2012A IN2012DN00592A IN 2012DN00592 A IN2012DN00592 A IN 2012DN00592A IN 592DEN2012 A IN592DEN2012 A IN 592DEN2012A IN 2012DN00592 A IN2012DN00592 A IN 2012DN00592A
Authority
IN
India
Prior art keywords
oxalate
compositions
methods
present
reducing
Prior art date
Application number
Inventor
Sidhu Harmeet
Li Qingshan
Blake Cowley Aaron
Golander Carl-Gustaf
Original Assignee
Oxthera Intellectual Property Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09164430.2A external-priority patent/EP2270138B1/en
Priority claimed from US12/497,275 external-priority patent/US8431122B2/en
Application filed by Oxthera Intellectual Property Ab filed Critical Oxthera Intellectual Property Ab
Publication of IN2012DN00592A publication Critical patent/IN2012DN00592A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)

Abstract

The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
IN592DEN2012 2009-07-02 2010-07-01 IN2012DN00592A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09164430.2A EP2270138B1 (en) 2009-07-02 2009-07-02 Purification and isolation of recombinant oxalate degrading enzymes
US12/497,275 US8431122B2 (en) 2009-07-02 2009-07-02 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
PCT/EP2010/003864 WO2011000523A1 (en) 2009-07-02 2010-07-01 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Publications (1)

Publication Number Publication Date
IN2012DN00592A true IN2012DN00592A (en) 2015-06-12

Family

ID=43028177

Family Applications (1)

Application Number Title Priority Date Filing Date
IN592DEN2012 IN2012DN00592A (en) 2009-07-02 2010-07-01

Country Status (16)

Country Link
US (1) US20120189604A1 (en)
EP (1) EP2449098B1 (en)
JP (2) JP2012531186A (en)
CN (2) CN102597225B (en)
BR (1) BRPI1013956B8 (en)
CA (2) CA2767039C (en)
DK (1) DK2449098T3 (en)
ES (1) ES2617917T3 (en)
HK (1) HK1210805A1 (en)
HU (1) HUE030905T2 (en)
IL (1) IL216873A (en)
IN (1) IN2012DN00592A (en)
LT (1) LT2449098T (en)
PL (1) PL2449098T3 (en)
PT (1) PT2449098T (en)
WO (1) WO2011000523A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
CN103540569A (en) * 2013-06-05 2014-01-29 黄虹寓 Calculus enzyme and preparation method thereof
US11077238B2 (en) * 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
CN104673765B (en) * 2014-12-22 2017-11-17 武汉康复得生物科技股份有限公司 One group of great-hearted oxalate oxidase and its application under physiological ph conditions
CN116124853B (en) * 2022-11-07 2024-01-16 东北农业大学 Electrochemical biosensor for detecting oxalic acid, preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) * 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
WO2004018634A2 (en) * 2002-08-20 2004-03-04 University Of Florida Polynucleotide encoding oxalate decarboxylase from aspergillus niger and methods of use
US6929940B1 (en) * 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
JP5047190B2 (en) * 2005-12-14 2012-10-10 オクセラ インコーポレイテッド Pharmaceutical compositions and methods for treating or preventing oxalate-related diseases
ATE499111T1 (en) * 2005-12-16 2011-03-15 Oxthera Inc COMPOSITIONS AND METHODS FOR OXALATE REDUCTION
ES2412254T3 (en) * 2006-08-02 2013-07-10 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use

Also Published As

Publication number Publication date
CN104805067A (en) 2015-07-29
HUE030905T2 (en) 2017-06-28
WO2011000523A1 (en) 2011-01-06
JP2012531186A (en) 2012-12-10
PL2449098T3 (en) 2017-06-30
CA2767039C (en) 2018-09-04
JP6220845B2 (en) 2017-10-25
US20120189604A1 (en) 2012-07-26
CA3012811A1 (en) 2011-01-06
DK2449098T3 (en) 2017-03-06
CA2767039A1 (en) 2011-01-06
EP2449098A1 (en) 2012-05-09
PT2449098T (en) 2017-03-10
HK1210805A1 (en) 2016-05-06
BRPI1013956B1 (en) 2021-04-06
EP2449098B1 (en) 2016-12-07
BRPI1013956B8 (en) 2021-05-25
CN102597225A (en) 2012-07-18
LT2449098T (en) 2017-05-25
ES2617917T3 (en) 2017-06-20
BRPI1013956A2 (en) 2019-04-09
JP2016121138A (en) 2016-07-07
IL216873A (en) 2017-07-31
CN102597225B (en) 2015-04-29
IL216873A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
MX2012007684A (en) Ligand-directed covalent modification of protein.
MX2012006549A (en) Compositions and methods comprising protease variants.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
MY166552A (en) Infant cereal comprising non-replicating probiotic microorganisms
MX2012000475A (en) Variants of plasminogen and plasmin.
EP2493464A4 (en) Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
TW200800994A (en) Inhibitors of E1 activating enzymes
MY161495A (en) Virus like particle compositions and methods of use
MY158325A (en) Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection
AU2011206532A8 (en) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
IN2012DN00801A (en)
MX2012001346A (en) Modified factor ix polypeptides and uses thereof.
MX2011013577A (en) Compositions and methods for treating amyotrophic lateral sclerosis.
IN2012DN00592A (en)
MX2010003013A (en) Inhibition of angiogenesis.
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
MY160560A (en) Compositions and methods for treatment of kidney disorders
MX2011008179A (en) Peptides for vaccine.
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
EP2597949A4 (en) Sub-micron compositions
WO2007117419A8 (en) Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
MY180681A (en) Compositions and methods for treatment of aortic fibrosis
IN2012DN03358A (en)